Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) to a hold rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 2.5%

NASDAQ:CPIX opened at $4.95 on Friday. Cumberland Pharmaceuticals has a one year low of $1.85 and a one year high of $7.25. The firm’s 50 day simple moving average is $3.01 and its 200 day simple moving average is $3.20. The company has a market cap of $74.04 million, a PE ratio of -20.63 and a beta of -0.53. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.The firm had revenue of $8.29 million for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of Cumberland Pharmaceuticals in the second quarter worth $34,000. Heron Bay Capital Management bought a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at $111,000. Two Sigma Investments LP raised its stake in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after acquiring an additional 27,980 shares during the period. 15.51% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.